$IMMP ADRs at wide 12% discount to $IMM.AU, which closed up 3.3% & above 50dma yest in Australia. $IMM.AU at .315 & AUD$ level at .6694 equals $2.11/sh for ADRs. Bell Potter in Top Pick report sees “multi-billion $ sales pot’l for uniquely acting efti”. immutep.com/investors-media/…
$IMM.AU Named Top ’23 Pick at 2 Australian firms. Chart of AUD$ that has weighed on $IMMP ADRs most of ’22 has been more constructive of late. $IMM.AU close yest at .33/sh with AUD$ at .6866 equals ~$2.27/sh for $IMMP. teapawt.net/immutep/status/1602973…
Replying to @Immutep
@Immutep is pleased to be selected as a 'top pick' by WILSONS' analyst Melissa Benson and Bell Potter Securities' analyst Tara Speranza in their respective 2023 outlook notes.
#LAG3 #biotech #healthcare #equityresearch #ASX $IMM $IMMP
2
3
cab971 retweeted
@Immutep We are pleased to share compelling data from TACTI-002 Phase II trial in 1st line #NSCLC at #SITC2022. A special thanks to Dr. Iams @VUMChealth for his oral presentation of our late-breaking abstract (#1470). Join our webcast today to learn more: immutep.com/files/content/in…
cab971 retweeted
#SITC22 | Wade Iams (@VUMChealth) discusses the TACTI-002 trial of eftilagimod alpha + pembro in 1st line #NSCLC
⭐ ORR | 40%
⭐ Median DOR | 21.6 mo
⭐ Encouraging ORR + PFS in PD-L1 low pts
@sitcancer #ImmunoOnc #LCSM
$IMMP Strong +8.5% move in $IMM.AU on >7MM sh to close at A$0.32 (15% above 50dma) on heels of late-breaking abstract oral presentation at #SITC2022. Equals $2.02/sh for $IMMP. Aussie $ weakness cont to impact ADRs.
Replying to @Immutep
$BU.TO Good to see KPMG on board as auditor to replace PWC. Burcon owns ~32% of Merit JV which includes $BG as ~29% partner. JV did >$6MM in sales in 1st yr & on track for solid yoy growth. Catalysts ahead: sunflower JV, new CEO, new collabs & higher $BG R&D plant protein spend.
“We are very pleased to have KPMG agree to come on board with us for the coming year..."
Press release: Burcon Announces Annual General Meeting Date
burcon.ca/2022/10/burcon-ann…
1
4
$IMMP Regeneron, Immutep Talk LAG-3 as ESMO Highlights New I-O Approaches. $IMM.AU unique MOA via #LAG3: “We activate APCs…which are involved in generating more CD8 & CD4 T cells and more NK cells…” so “potentially more targets for anti-PD-1 to work on.”
biospace.com/article/regener…
$IMMP More on unique attributes of $IMM.AU lead clinical candidate, efti, to activate adaptive/innate system from conf. Covered broad #LAG3 pipeline & strong clinical results from efti+Keytruda vs $MRK Keytruda mono in NSCLC & HNSCC across all PD-L1 levels teapawt.net/immutep/status/1576416…
$IMMP On heels of Fast Track news, good to see 3 abstracts at #SITC2022 incl initial data from triple combo trial that may capitalize on efti’s synergy w both chemo & IO (Keytruda) plus a Late Breaking Abstract (more details on Nov 2 as per press release) globenewswire.com/news-relea…
$BRCN $BU.TO Good news via non-dilutive $10 million credit line from largest shareholder Firewood (wholly-owned by Director Alan Chan). Catalysts ahead incl (1) new CEO, (2) new #plantbased protein partnerships that are “progressing well”, and (3) addt’l strategic collaborations
1
10
$BRCN $BU.TO 10/ Another good article on Burcon/Merit’s approach to replace #methylcellulose, in particular noting “pretty remarkable gelation” with proteins that go thru their proprietary membrane filtration process. “We knew we had something special…” foodnavigator-usa.com/Articl…
1
3
$STXS Good news re: MAGIC catheter. On just existing biz leads to $46-48MM in high margin annual revs not incl system sales. Future launches incl cryoablation & Pulsed-field ablation catheters, as well as new guidewires for its >100 installed RMN systems. ir.stereotaxis.com/news-rele…
4
$IMMP In Australia $IMM.AU was up ~7% to ~$2.22 sh IMMP. Tax loss selling season in Australia near end (June 30). Good interview w CEO; worth listening to all. At 37:00 mark talks of “very nice reception/reflection of data by…KOLs, PIs, potential/actual strategic partners” etc.
Episode 43 of the Benchtop Bios Podcast featuring Marc Voigt, CEO of @Immutep who discusses how the first LAG-3-targeting drug's approval, and as of ASCO 2022, Immutep’s LAG-3 asset is poised to replace IO/chemo in the front-line setting for NSCLC. Listen: lifesci.events/IMMP2
























































